oxybutynin transdermal (Rx, OTC)

Brand and Other Names:Oxytrol, Oxytrol For Women
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

transdermal patch

  • 3.9mg/day
more...

Overactive Bladder

Indicated for symptom relief in uninhibited neurogenic or reflex neurogenic bladder (urge incontinence, frequency and urgency)

Apply 1 patch (releases 3.9 mg/day) twice/week (ie, q3-4 days)

Rotate application sites; need not be removed during bathing, swimming, exercising, or sleeping

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and oxybutynin transdermal

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            NOTE: anticholinergic adverse effects are less with transdermal application compared with oral administration

            >10%

            Pruritus at application site (14-16.8%)

            1-10%

            Xerostomia (4.1-9.6%)

            Erythema at application site (5.6-8.3%)

            Constipation (3.3%)

            Vesicles, macules, rash at application site (2.5-3.3%)

            Diarrhea (3.2%)

            Blurred vision (2.5%)

            Dysuria (2.4%)

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Gastric retention

            Uncontrolled narrow-angle glaucoma

            Urinary retention

            Conditions that severely decrease GI motility

            Cautions

            Caution with clinically significant bladder outflow obstruction because of the risk of urinary retention

            Caution with gastrointestinal obstructive disorders or decreased intestinal motility because of the risk of gastric retention

            Caution with GERD and/or those taking drugs that can cause or exacerbate esophagitis (eg, bisphosphonates)

            Discontinue if skin hypersensitivity occurs

            Caution with other anticholinergics (antimuscarinics); may increase risk for xerostomia, constipation, headache, dizziness, somnolence, and blurred vision

            Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oral oxybutynin; in the event of angioedema, oxybutynin containing products should be discontinued and appropriate therapy promptly provided

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: Unknown whether distributed in breast milk

            Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Exerts antispasmodic and antimuscarinic effects on smooth muscle; decreases uninhibited contractions, and delays desire to void; increases bladder capacity

            Pharmacokinetics

            Peak Plasma Concentration: 3-6.6 ng/mL

            Metabolism: bypasses first-pass in liver by CYP3A4, AUC ratio of N-desethyloxybutynin (active metabolite) to parent compound is 1:1

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous